Aspire Biopharma Holdings, Inc. 8-K

What Happened
Aspire Biopharma Holdings, Inc. (ASBP) filed an 8‑K reporting that on January 8, 2026 the Board confirmed the share limits and certain terms of the company's 2024 Stock Incentive Plan. The Plan was previously approved by stockholders at an extraordinary meeting on February 4, 2025. On the same date (January 8, 2026) the Board also approved form award agreements for restricted stock units (RSUs) and stock options to be used for grants under the Plan.

Key Details

• The Board determined a share limit of 4,890,000 shares to be included in the 2024 Stock Incentive Plan.
• The Plan was approved by shareholders on February 4, 2025 at an extraordinary meeting.
• On January 8, 2026 the Board approved standard form award agreements for RSUs and Options (RSUs convert to one share upon vesting; Options grant the right to buy shares at a set exercise price), subject to vesting and continued service.
• Full text of the Plan and the award agreement forms were filed as exhibits to the 8‑K.

Why It Matters
This filing formalizes the company’s equity compensation framework, enabling Aspire to grant stock‑based awards to employees, directors and consultants to attract and retain talent and align pay with shareholder interests. The 4,890,000‑share allocation represents potential future dilution; investors should monitor subsequent award grants, vesting schedules and exercise prices, as those details affect outstanding share count and the company’s capital structure.